Dr. Kim Discusses PD-L1 as a Biomarker in Lung Cancer

Edward S. Kim, MD
Published: Wednesday, Dec 20, 2017



Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses PD-L1 as a biomarker in lung cancer.

Although PD-L1 has been contested as a reliable biomarker in lung cancer, Kim says that it is useful for selecting patients to receive frontline immunotherapy.
 


Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses PD-L1 as a biomarker in lung cancer.

Although PD-L1 has been contested as a reliable biomarker in lung cancer, Kim says that it is useful for selecting patients to receive frontline immunotherapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x